Natalie Moody
Psychiatric/Mental Health · Winter Haven, FLNPI 1740563543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,950 of the $74,968 with a category attached, or 88.0%. AbbVie accounts for 85.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $23,804 and has fallen 51.5% since, to $11,554 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 456 payments — averaging $164.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$64K
- Teva Pharmaceuticals USA, Inc.$6K
- Otsuka America Pharmaceutical, Inc.$647
- Alkermes, Inc.$502
- Neurocrine Biosciences, Inc.$476
- Lundbeck LLC$472
- plus $3K from 14 others
What the payments were for
- Speaking & faculty fees$65,95088%
- Travel & lodging$1,3012%
- Food & beverage$7,49410%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 154 | $63,762 |
| Teva Pharmaceuticals USA, Inc. | 40 | $6,258 |
| Otsuka America Pharmaceutical, Inc. | 43 | $647 |
| Alkermes, Inc. | 23 | $502 |
| Neurocrine Biosciences, Inc. | 28 | $476 |
| Lundbeck LLC | 30 | $472 |
| Johnson & Johnson | 22 | $434 |
| Supernus Pharmaceuticals, Inc. | 18 | $416 |
| Vanda Pharmaceuticals Inc. | 19 | $401 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $244 |
| Tris Pharma Inc | 13 | $239 |
| E.r. Squibb & Sons, L.L.C. | 9 | $194 |
| Avanir Pharmaceuticals, Inc. | 10 | $166 |
| Axsome Therapeutics, Inc. | 8 | $144 |
| Livanova USA, Inc. | 1 | $130 |
| Indivior Inc. | 2 | $50 |
| Eisai Inc. | 3 | $47 |
| Novo Nordisk | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$61,553
- Austedo XR$3,318
- UZEDY$2,023
- QELBREE$154
- VNS Therapy Symmetry Model 8103 Generator$130
How this compares
$74,968 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 48 | $141,716 |
| Invega TrinzaPaliperidone Palmitate | 14 | $110,304 |
| Abilify MaintenaAripiprazole | 25 | $77,833 |
| VraylarCariprazine Hcl | 54 | $76,356 |
| RexultiBrexpiprazole | 12 | $23,175 |
| Aripiprazole | 331 | $20,887 |
| Lurasidone Hcl | 108 | $16,691 |
| Ziprasidone Hcl | 111 | $7,882 |
| BelsomraSuvorexant | 15 | $6,326 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,625 |
| Alprazolam | 786 | $5,392 |
| Doxepin Hcl | 105 | $5,364 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,841 |
| Trazodone Hcl | 418 | $4,749 |
| Bupropion XlBupropion Hcl | 180 | $4,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $434 | $252,02062 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $647 | $101,00837 claims |
| AbbVieVraylar | $63,762 | $76,35654 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $244 | $10,46624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Winter Haven
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
- Linda SkalskyGainesville$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.